Federal Register / Vol. 65, No. 76 / Wednesday, April 19, 2000 / Notices 21003

individuals associated with the contract

proposals, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Drug Abuse Special Emphasis Panel ‘‘Drug

Abuse Prevention Dissemination’’.

Date: April 19, 2000.

Time: 11 am to 1 pm.

Agenda: To review and evaluate contract

proposals.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Lyle Furr, Contract Review

Specialist, Office of Extramural Affairs,

National Institute on Drug Abuse, National

Institutes of Health, DHHS, 6001 Executive

Boulevard, Room 3158, MSC 9547, Bethesda,

MD 20892–9547, (301) 435–1439.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.277, Drug Abuse Scientist

Development Award for Clinicians, Scientist

Development Awards, and Research Scientist

Awards; 93.278, Drug Abuse National

Research Service Awards for Research

Training; 93.279, Drug Abuse Research

Programs, National Institutes of Health, HHS)

Dated: April 13, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–9807 Filed 4–18–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of

Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: April 19, 2000.

Time: 1:30 pm to 2:30 pm.

Agenda: To review and evaluate grant

applications.

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: Joseph Kimm, PhD,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5178

MSC 7844, Bethesda, MD 20892, (301) 435–

1249.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: April 28, 2000.

Time: 1 pm to 2 pm.

Agenda: To review and evaluate grant

applications.

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: H. Mac Stiles, DDS, PhD,

MPH, Scientific Review Administrator,

Center for Scientific Review, National

Institutes of Health, 6701 Rockledge Drive,

Room 4108, MSC 7816, Bethesda, MD 20892,

301–435–1785.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: May 1, 2000.

Time: 2 pm to 5 pm.

Agenda: To review and evaluate grant

applications.

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: Marcelina B. Powers,

DVM, MS, Scientific Review Administrator,

Center for Scientific Review, National

Institutes of Health, 6701 Rockledge Drive,

Room 4152, MSC 7804, Bethesda, MD 20892,

(301) 435–1720.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: May 3, 2000.

Time: 1 pm to 4 pm.

Agenda: To review and evaluate grant

applications.

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: Carl D. Banner, PhD,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5212,

MSC 7850, Bethesda, MD 20892, (301) 435–

1251, bannerc@drg.nih.gov

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: May 3, 2000.

Time: 2 pm to 3 pm.

Agenda: To review and evaluate grant

applications.

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: Marcelina B. Powers,

DVM, MS, Scientific Review Administrator,

Center for Scientific Review, National

Institutes of Health, 6701 Rockledge Drive,

Room 4152, MSC 7804, Bethesda, MD 20892

(301) 435–1720.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333,

93.337, 93.393–93.396, 93.837–93.844,

93.846–93.878, 93.892, 93.893, National

Institutes of Health, HHS)

Dated: April 13, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–9806 Filed 4–18–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospect Grant of Exclusive License:

Therapeutic and Diagnostic Uses of

Novel Thiolesters for HIV and Other

Applications

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 35 U.S.C. 209 (c)(1) and 37 CFR

404.7 (a) (1) (i) that the National

Institutes of Health (NIH), Department

of Health and Human Services (DHHS),

is contemplating the grant of an

exclusive license worldwide to practice

the inventions embodied in patents

under ‘‘Supplementary Information’’ to

Achillion Pharmaceuticals, Inc., having

a place of business in New Haven,

Connecticut. The patent rights in these

inventions have been assigned to the

government of the United States of

America.

DATES: Only written comments and/or

license applications which are received

by the NIH Office of Technology

Transfer on or before June 19, 2000 will

be considered.

ADDRESSES: Requests for a copy of these

patent applications, inquiries,

comments, and other materials relating

to the contemplated license should be

directed to: Mr. J.P. Kim, Technology

Licensing Specialist, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, Maryland 20852–

3804; Telephone: (301) 496–7056, ext.

264; Facsimile: (301) 402–0220. A

signed Confidential Disclosure

Agreement (CDA) may be required to

receive copies of the patent application.

SUPPLEMENTARY INFORMATION: The patent

applications to be licensed are: ‘‘Novel

Thiolesters and Uses Thereof’’, U.S.

Provisional Patent Application Serial